Keiichiro Hattori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Keiichiro Hattori has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Mamiko Sakata-Yanagimoto
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
13 shared publications - Shigeru Chiba
Institute of Medicine, University of Tsukuba
11 shared publications - Yasuhito Suehara
Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
8 shared publications Ryota Matsuoka
Department of Pathology Institute of Medicine, University of Tsukuba Tsukuba Ibaraki Japan
6 shared publications- Yoshiaki Abe
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
6 shared publications Yasuhito Suehara
Department of Hematology University of Tsukuba Hospital Tsukuba Ibaraki Japan
5 shared publications
Latest Publications
- Open Access
- 10 May 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (9) , e70955
Real‐World Data on the p. Gly17Val RHOA Mutation in Diagnosing T Follicular Helper Cell Lymphomas
Background: T follicular helper (Tfh) cell lymphomas, including their most prevalent form, angioimmunoblastic T‐cell lymphoma, frequently present with clinical symptoms, such as fever and rash, accompanied by substantial immune cell infiltration within the tumor microenvironment. These features often obscure the distinction between Tfh lymphoma and other autoimmune or inflammatory conditions. Notably, the p.Gly17Val RHOA (G17V) mutation is commonly associated with Tfh lymphomas, including angioimmunoblastic T‐cell lymphoma, suggesting that testing for the G17V mutation may serve as a valuable diagnostic tool. However, it remains unclear which patients would benefit the most from G17V mutation testing. Methods: In this study, we retrospectively reviewed the medical records of 224 patients tested for the G17V mutation as part of routine clinical practice. Results: We detected G17V in 17 patients. Among Tfh lymphoma cases, the sensitivity and specificity of the G17V test were 0.533 and 0.955, respectively. We further explored the association between G17V positivity and the clinical features of patients undergoing testing for the first time ( n = 186). The G17V mutation was more frequent in patients presenting with lymphadenopathy in combination with fever or skin rash and elevated soluble interleukin‐2 receptor levels ( p = 0.002). The median time from G17V test submission to results was 11.6 d shorter than that for pathological diagnosis ( p = 0.0009). Conclusions: Given the noninvasive nature of the G17V test, its rapid administration to appropriate patients is expected to enable faster and more efficient diagnosis of Tfh lymphomas compared with conventional methods.
- 10 May 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (9) , e70955
Open AccessReal‐World Data on the p. Gly17Val RHOA Mutation in Diagnosing T Follicular Helper Cell Lymphomas
Background: T follicular helper (Tfh) cell lymphomas, including their most prevalent form, angioimmunoblastic T‐cell lymphoma, frequently present with clinical symptoms, such as fever and rash, accompanied by substantial immune cell infiltration within the tumor microenvironment. These features often obscure the distinction between Tfh lymphoma and other autoimmune or inflammatory conditions. Notably, the p.Gly17Val RHOA (G17V) mutation is commonly associated with Tfh lymphomas, including angioimmunoblastic T‐cell lymphoma, suggesting that testing for the G17V mutation may serve as a valuable diagnostic tool. However, it remains unclear which patients would benefit the most from G17V mutation testing. Methods: In this study, we retrospectively reviewed the medical records of 224 patients tested for the G17V mutation as part of routine clinical practice. Results: We detected G17V in 17 patients. Among Tfh lymphoma cases, the sensitivity and specificity of the G17V test were 0.533 and 0.955, respectively. We further explored the association between G17V positivity and the clinical features of patients undergoing testing for the first time ( n = 186). The G17V mutation was more frequent in patients presenting with lymphadenopathy in combination with fever or skin rash and elevated soluble interleukin‐2 receptor levels ( p = 0.002). The median time from G17V test submission to results was 11.6 d shorter than that for pathological diagnosis ( p = 0.0009). Conclusions: Given the noninvasive nature of the G17V test, its rapid administration to appropriate patients is expected to enable faster and more efficient diagnosis of Tfh lymphomas compared with conventional methods.
- Open Access
Association between microenvironment‐related genes and prognosis of primary central nervous system lymphoma
Background: Primary central nervous system lymphoma (PCNSL) is a rare lymphoid malignancy. Systemic profiling of the PCNSL tumor microenvironment (TME) was previously conducted through gene expression analysis. We investigated the prognostic impact of TME on survival to establish novel prognostic biomarkers in PCNSL patients.Methods: We analyzed expression levels of 770 neuroinflammation‐related (NFR) genes via NanoString nCounter technology in tumor samples from 30 PCNSL patients. Genes related to the “recurrence group (RG)” or “non‐recurrence group (NRG)” were identified and validated using whole transcriptomic analysis of an independent PCNSL cohort (n = 30).Results: Forty‐five of 770 NFR genes were highly expressed in the RG (3‐year overall survival (OS, 22.2%), compared with the NRG group (3‐year OS 66.7%). Signatures related to glial cells were enriched in the RG‐associated gene set. Multivariate analysis revealed that high expressions of TUBB4A (p = 0.028, HR: 3.88), S100B (p = 0.046, HR: 3.093), and SLC6A1 (p = 0.034, HR: 3.765) were significantly related to death. Expression levels of these three genes were also significantly associated with poor OS in the validation cohort. Immunohistochemical staining against TUBB4A, S100B, and proteins specific to glial cells (GFAP, OLIG2, and CD68) revealed significantly higher positivity in RG glial cells.Conclusion: These data suggest that TME‐related genes play a crucial role in the pathogenesis of PCNSL, complementing the well‐known involvement of the NF‐kB signaling pathway. TME targeting, especially glial cell‐specific proteins, may thus open new and complementary avenues of therapy for all stages of PCNSL.
Open AccessAssociation between microenvironment‐related genes and prognosis of primary central nervous system lymphoma
Background: Primary central nervous system lymphoma (PCNSL) is a rare lymphoid malignancy. Systemic profiling of the PCNSL tumor microenvironment (TME) was previously conducted through gene expression analysis. We investigated the prognostic impact of TME on survival to establish novel prognostic biomarkers in PCNSL patients.Methods: We analyzed expression levels of 770 neuroinflammation‐related (NFR) genes via NanoString nCounter technology in tumor samples from 30 PCNSL patients. Genes related to the “recurrence group (RG)” or “non‐recurrence group (NRG)” were identified and validated using whole transcriptomic analysis of an independent PCNSL cohort (n = 30).Results: Forty‐five of 770 NFR genes were highly expressed in the RG (3‐year overall survival (OS, 22.2%), compared with the NRG group (3‐year OS 66.7%). Signatures related to glial cells were enriched in the RG‐associated gene set. Multivariate analysis revealed that high expressions of TUBB4A (p = 0.028, HR: 3.88), S100B (p = 0.046, HR: 3.093), and SLC6A1 (p = 0.034, HR: 3.765) were significantly related to death. Expression levels of these three genes were also significantly associated with poor OS in the validation cohort. Immunohistochemical staining against TUBB4A, S100B, and proteins specific to glial cells (GFAP, OLIG2, and CD68) revealed significantly higher positivity in RG glial cells.Conclusion: These data suggest that TME‐related genes play a crucial role in the pathogenesis of PCNSL, complementing the well‐known involvement of the NF‐kB signaling pathway. TME targeting, especially glial cell‐specific proteins, may thus open new and complementary avenues of therapy for all stages of PCNSL.
- Open Access
- 17 September 2024
- Published by Wiley in Cancer Science
- Vol. 115 (11) , 3788-3794
Genetic profiles and clinical features in subcutaneous panniculitis‐like T‐cell lymphomas
Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) is a rare peripheral T‐cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five‐year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated whole‐exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5‐year median follow‐up, one patient developed autoimmune‐related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for long‐term follow‐up.
- 17 September 2024
- Published by Wiley in Cancer Science
- Vol. 115 (11) , 3788-3794
Open AccessGenetic profiles and clinical features in subcutaneous panniculitis‐like T‐cell lymphomas
Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) is a rare peripheral T‐cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five‐year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated whole‐exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5‐year median follow‐up, one patient developed autoimmune‐related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for long‐term follow‐up.
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 430
Distinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization
Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 430
Open AccessDistinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization
Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 5608
Investigation of Clonal Hematopoiesis in New Japanese Cohort
Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 5608
Open AccessInvestigation of Clonal Hematopoiesis in New Japanese Cohort
Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund
- 7 August 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 768-776
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia
Objectives: Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA.Methods: We retrospectively evaluated the efficacy and safety of IST2 with rATG (IST2‐rATG) in 19 consecutive patients with relapsed or refractory AA who received first‐line IST with rATG in two centers between 2009 and 2020.Results: The overall 6‐month response rate of the patients was 58%. The response rates were similar between patients with relapsed and refractory AA. The presence of glycophosphatidylinositol‐deficient blood cells was associated with a better response to IST2‐rATG. Despite retreatment with the same rATG, serum disease and severe allergic reactions were not observed.Conclusion: IST2‐rATG is effective and safe for the treatment of adult patients with relapsed and refractory AA after receiving first‐line IST with rATG.
- 7 August 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 768-776
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia
Objectives: Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA.Methods: We retrospectively evaluated the efficacy and safety of IST2 with rATG (IST2‐rATG) in 19 consecutive patients with relapsed or refractory AA who received first‐line IST with rATG in two centers between 2009 and 2020.Results: The overall 6‐month response rate of the patients was 58%. The response rates were similar between patients with relapsed and refractory AA. The presence of glycophosphatidylinositol‐deficient blood cells was associated with a better response to IST2‐rATG. Despite retreatment with the same rATG, serum disease and severe allergic reactions were not observed.Conclusion: IST2‐rATG is effective and safe for the treatment of adult patients with relapsed and refractory AA after receiving first‐line IST with rATG.
- 1 January 2022
- Vol. 63 (5) , 347-352
[Late-onset refractory autoimmune hemolytic anemia following autologous hematologic recovery after allo-HSCT in aplastic anemia-PNH syndrome].
A 31-year-old man underwent allogeneic bone marrow transplantation (BMT) for the treatment of transfusion-dependent aplastic anemia (AA) after conditioning with a regimen including fludarabine, cyclophosphamide, and antithymocyte globulin. The patient developed a late graft rejection on day 103 and showed autologous hematologic recovery not requiring transfusions on day 76. Peripheral blood leukocytes were of 100% recipient origin on day 103, and paroxysmal nocturnal hematuria (PNH)-type granulocytes were detected 5 months after BMT. The patient suddenly experienced hemolytic symptoms triggered by cold stimulation, and was diagnosed with autoimmune hemolytic anemia (AIHA) 37 months after BMT. Although anemia was ameliorated by prednisolone (PSL), hemolytic attacks repeatedly occurred, which became refractory to corticosteroids. Moreover, the patient underwent a splenectomy for the steroid-resistant AIHA and achieved AIHA remission without the need for PSL at 53 months after BMT. The immune tolerance breakdown to erythrocyte antigens was thought to have occurred due to various factors including immune AA, medication, cold stimulation, and infection, leading to AIHA development in this case.
- 1 January 2022
- Vol. 63 (5) , 347-352
[Late-onset refractory autoimmune hemolytic anemia following autologous hematologic recovery after allo-HSCT in aplastic anemia-PNH syndrome].
A 31-year-old man underwent allogeneic bone marrow transplantation (BMT) for the treatment of transfusion-dependent aplastic anemia (AA) after conditioning with a regimen including fludarabine, cyclophosphamide, and antithymocyte globulin. The patient developed a late graft rejection on day 103 and showed autologous hematologic recovery not requiring transfusions on day 76. Peripheral blood leukocytes were of 100% recipient origin on day 103, and paroxysmal nocturnal hematuria (PNH)-type granulocytes were detected 5 months after BMT. The patient suddenly experienced hemolytic symptoms triggered by cold stimulation, and was diagnosed with autoimmune hemolytic anemia (AIHA) 37 months after BMT. Although anemia was ameliorated by prednisolone (PSL), hemolytic attacks repeatedly occurred, which became refractory to corticosteroids. Moreover, the patient underwent a splenectomy for the steroid-resistant AIHA and achieved AIHA remission without the need for PSL at 53 months after BMT. The immune tolerance breakdown to erythrocyte antigens was thought to have occurred due to various factors including immune AA, medication, cold stimulation, and infection, leading to AIHA development in this case.
- Open Access
- 21 November 2021
- Published by Wiley in Cancer Science
- Vol. 113 (1) , 362-364
Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples
- 21 November 2021
- Published by Wiley in Cancer Science
- Vol. 113 (1) , 362-364
Open AccessIntratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples
- Open Access
- 17 October 2021
- Published by Wiley in Cancer Science
- Vol. 112 (12) , 4931-4943
Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model
Immune cells harboring somatic mutations reportedly infiltrate cancer tissues in patients with solid cancers and accompanying clonal hematopoiesis. Loss‐of‐function TET2 mutations are frequently observed in clonal hematopoiesis in solid cancers. Here, using a mouse lung cancer model, we evaluated the activity of Tet2‐deficient immune cells in tumor tissues. Myeloid‐specific Tet2 deficiency enhanced tumor growth in mice relative to that seen in controls. Single‐cell sequencing analysis of immune cells infiltrating tumors showed relatively high expression of S100a8/S100a9 in Tet2‐deficient myeloid subclusters. In turn, treatment with S100a8/S100a9 promoted Vegfa production by cancer cells, leading to a marked increase in the tumor vasculature in Tet2‐deficient mice relative to controls. Finally, treatment of Tet2‐deficient mice with an antibody against Emmprin, a known S100a8/S100a9 receptor, suppressed tumor growth. These data suggest that immune cells derived from TET2‐mutated clonal hematopoiesis exacerbate lung cancer progression by promoting tumor angiogenesis and may provide a novel therapeutic target for lung cancer patients with TET2‐mutated clonal hematopoiesis.
- 17 October 2021
- Published by Wiley in Cancer Science
- Vol. 112 (12) , 4931-4943
Open AccessTet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model
Immune cells harboring somatic mutations reportedly infiltrate cancer tissues in patients with solid cancers and accompanying clonal hematopoiesis. Loss‐of‐function TET2 mutations are frequently observed in clonal hematopoiesis in solid cancers. Here, using a mouse lung cancer model, we evaluated the activity of Tet2‐deficient immune cells in tumor tissues. Myeloid‐specific Tet2 deficiency enhanced tumor growth in mice relative to that seen in controls. Single‐cell sequencing analysis of immune cells infiltrating tumors showed relatively high expression of S100a8/S100a9 in Tet2‐deficient myeloid subclusters. In turn, treatment with S100a8/S100a9 promoted Vegfa production by cancer cells, leading to a marked increase in the tumor vasculature in Tet2‐deficient mice relative to controls. Finally, treatment of Tet2‐deficient mice with an antibody against Emmprin, a known S100a8/S100a9 receptor, suppressed tumor growth. These data suggest that immune cells derived from TET2‐mutated clonal hematopoiesis exacerbate lung cancer progression by promoting tumor angiogenesis and may provide a novel therapeutic target for lung cancer patients with TET2‐mutated clonal hematopoiesis.
- Open Access
- 23 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (4) , 585-594
Retrospective analyses of other iatrogenic immunodeficiency‐associated lymphoproliferative disorders in patients with rheumatic diseases
Summary: Other iatrogenic immunodeficiency‐associated lymphoproliferative disorders (OIIA‐LPDs) occur in patients receiving immunosuppressive drugs for autoimmune diseases; however, their clinicopathological and genetic features remain unknown. In the present study, we analysed 67 patients with OIIA‐LPDs, including 36 with diffuse large B‐cell lymphoma (DLBCL)‐type and 19 with Hodgkin lymphoma (HL)‐type. After discontinuation of immunosuppressive drugs, regression without relapse was achieved in 22 of 58 patients. Spontaneous regression was associated with Epstein–Barr virus positivity in DLBCL‐type (P = 0·013). The 2‐year overall survival and progression‐free survival (PFS) at a median follow‐up of 32·4 months were 92·7% and 72·1% respectively. Furthermore, a significant difference in the 2‐year PFS was seen between patients with DLBCL‐type and HL‐type OIIA‐LPDs (81·0% vs. 40·9% respectively, P = 0·021). In targeted sequencing of 47 genes in tumour‐derived DNA from 20 DLBCL‐type OIIA‐LPD samples, histone‐lysine N‐methyltransferase 2D (KMT2D; eight, 40%) and tumour necrosis factor receptor superfamily member 14 (TNFRSF14; six, 30%) were the most frequently mutated genes. TNF alpha‐induced protein 3 (TNFAIP3) mutations were present in four patients (20%) with DLBCL‐type OIIA‐LPD. Cases with DLBCL‐type OIIA‐LPD harbouring TNFAIP3 mutations had shorter PFS and required early initiation of first chemotherapy. There were no significant factors for spontaneous regression or response rates according to the presence of mutations. Overall, OIIA‐LPDs, especially DLBCL‐types, showed favourable prognoses.
- 23 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (4) , 585-594
Open AccessRetrospective analyses of other iatrogenic immunodeficiency‐associated lymphoproliferative disorders in patients with rheumatic diseases
Summary: Other iatrogenic immunodeficiency‐associated lymphoproliferative disorders (OIIA‐LPDs) occur in patients receiving immunosuppressive drugs for autoimmune diseases; however, their clinicopathological and genetic features remain unknown. In the present study, we analysed 67 patients with OIIA‐LPDs, including 36 with diffuse large B‐cell lymphoma (DLBCL)‐type and 19 with Hodgkin lymphoma (HL)‐type. After discontinuation of immunosuppressive drugs, regression without relapse was achieved in 22 of 58 patients. Spontaneous regression was associated with Epstein–Barr virus positivity in DLBCL‐type (P = 0·013). The 2‐year overall survival and progression‐free survival (PFS) at a median follow‐up of 32·4 months were 92·7% and 72·1% respectively. Furthermore, a significant difference in the 2‐year PFS was seen between patients with DLBCL‐type and HL‐type OIIA‐LPDs (81·0% vs. 40·9% respectively, P = 0·021). In targeted sequencing of 47 genes in tumour‐derived DNA from 20 DLBCL‐type OIIA‐LPD samples, histone‐lysine N‐methyltransferase 2D (KMT2D; eight, 40%) and tumour necrosis factor receptor superfamily member 14 (TNFRSF14; six, 30%) were the most frequently mutated genes. TNF alpha‐induced protein 3 (TNFAIP3) mutations were present in four patients (20%) with DLBCL‐type OIIA‐LPD. Cases with DLBCL‐type OIIA‐LPD harbouring TNFAIP3 mutations had shorter PFS and required early initiation of first chemotherapy. There were no significant factors for spontaneous regression or response rates according to the presence of mutations. Overall, OIIA‐LPDs, especially DLBCL‐types, showed favourable prognoses.